Trade analysis: Novo Nordisk wins the first round of the oral obesity duel

Novo Nordisk's oral semaglutide pill, sold under the Wegovy brand, is getting about four times as many weekly prescriptions as Eli Lilly's new obesity pill, Foundayo, according to prescription data from IQVIA cited by analysts at Citi and reported by Fierce Pharma ^[2]. For the week ending September 11, 2026, the Wegovy pill logged roughly 183,000 total prescriptions, up slightly from 181,000 the week before, while Foundayo climbed nearly 8% to about 47,500 scripts ^[2].

The gap traces back to timing and coverage. The Wegovy pill launched about three months before Foundayo did, and it had full commercial insurance coverage from its very first week on the market ^[2]. Foundayo did not reach that same coverage status until CVS Caremark, the last of the three major pharmacy benefit managers, added it on June 1, 2026 ^[2]. In the early weeks, Foundayo's prescriptions were essentially flat at around 20,000 a week even three months after its debut — a level the Wegovy pill had already reached within two to three weeks of its own launch ^[2].

Foundayo has picked up speed since the coverage gap closed. It broke past 40,000 weekly scripts for the first time by late August, and Lilly's own leadership has pointed to a shift. Ilya Yuffa, president of Lilly USA, said the company is "starting to see an inflection point on Foundayo now" after securing access across the three major pharmacy benefit managers in June and ramping up direct-to-consumer marketing ^[2]. Still, Foundayo's second-quarter sales of $98 million globally, including $67 million in the U.S., came in below what many analysts expected ^[2]. Citi analysts also flagged that IQVIA's tracking may be undercounting Foundayo prescriptions filled through telehealth channels, meaning the real gap could be smaller than the headline numbers suggest ^[2].

Zooming out to the full GLP-1 market, Eli Lilly's tirzepatide products now hold close to 57% of total prescriptions across diabetes and obesity, up from about 49.5% a year earlier, while Novo Nordisk's semaglutide products have held roughly steady at 37% ^[2]. Within Novo's own Wegovy franchise, the oral pill has consistently made up about a third to 35% of all Wegovy prescriptions, a share that has plateaued rather than kept climbing ^[2].

Why it matters for patients

For people deciding between an oral GLP-1 option, insurance coverage timing has mattered as much as the drug itself so far. Because CVS Caremark did not add Foundayo to its formulary until June 1, 2026, patients whose plans route through that pharmacy benefit manager may have faced higher out-of-pocket costs or coverage denials for Foundayo in the months right after its launch, even if they and their doctor preferred it ^[2]. That kind of coverage lag can shape which pill a patient ends up trying, independent of how the drugs compare clinically.

The Medicare GLP-1 Bridge program, which began July 1, 2026, has also started covering certain weight-loss medications, including Foundayo, for a $50 monthly copay, which could change access for Medicare patients going forward ^[2]. More broadly, oral GLP-1 drugs are expanding the overall market: total GLP-1 prescriptions rose 5.4% over a recent four-week stretch, compared with a 6.8% decline in the same period a year earlier, a shift Citi analysts linked to pills drawing in patients who had been reluctant to use injections ^[2]. The specific list prices for the Wegovy pill and Foundayo are not detailed in current reporting, so patients weighing the two should not assume cost parity with the injectable versions.

What happens next

Fierce Pharma's tracker updates weekly, so the prescription gap between the two pills will keep shifting as Foundayo's formulary access matures and Lilly's marketing push continues ^[2]. Whether Foundayo can close the four-to-one gap, or whether Novo Nordisk's early lead proves durable, is not yet known.